The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...

Tivoxavir marboxil (TXM), administered as a single dose in non-human primates, significantly reduced lung viremia and prevented weight loss, two ...

As the trend towards the international dispersion of certain value chain activities produces challenges, discover policies to meet these Tax transparency and international co-operation Enhanced ...

This guide covers all the logo design rules, best practices, tips, examples, and more to equip you with the knowledge for crafting brilliant logos. Logos are one of the most vital elements of any ...

From its origins in a garage to becoming one of the most recognisable symbols in the world, explore the story behind the iconic Apple logo design. Apple is a company that has changed the technology ...

Open innovation in medical and pharmaceutical research has grown steadily over the last decade. However, the performance of the published literature in terms of the scientific impact and gaining ...

The occasion was the 2025 PRWeek Healthcare Awards, a celebration of the sector that crafts the public’s perception of pharmaceutical ... banner emblazoned with logos of corporate sponsors.

With a thrust on strong operations over the past decade, Indian pharma production has outpaced global growth by over two times. Image: Sanjay Rawat India’s pharmaceutical sector is at a tipping point ...

For years, Jeff Simmons — the president and CEO of the large US pharmaceutical company Elanco — ridiculed a seemingly unlikely target on social media: the plant-based meat industry.

Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Creating a strong brand identity ...

Recursion Pharmaceuticals showcased significant progress in advancing its pipeline and platform capabilities, supported by clinical data readouts and partnerships with Roche and Sanofi.

So the company's revenue streams suggest a split between a long-term royalty base of revenue and then viable drug candidates and short-term partnership-based deals with existing pharma companies.